LIDOCAINE HYDROCHLORIDE AND DEXTROSE INJ

Lidocaine hydrochloride and dextrose injection in 500 mL premixed bags, containing 0.4% lidocaine and 5% dextrose, is being procured under solicitation SPE2DP-26-T-4454 with a unit of issue defined as a package of 18 bags. The item must meet stringent technical and quality standards outlined in the DLA Master List of Technical and Quality Requirements, and packaging must comply with Medical Marking Standard No. 1, superseding MIL-STD-129. At least 16 months of shelf life must remain at the time of delivery to the first government activity, as the product has a fixed 18-month non-extendable shelf life under Type I (Code K) requirements. The drug is regulated by the FDA, and contractors must ensure full compliance with all applicable federal standards for commercial packaging, including ASTM D3951 where applicable, though DLA requirements take precedence. The product is currently in limited supply due to manufacturing constraints, and only Baxter Healthcare Corp’s specific NDC 00338-0409-03 and part number 2B0973P are authorized. Delivery is required within five days of award, FOB destination, with zero variance permitted in quantity. The shipment must be sent via traceable and expedited means to the USS THEODORE ROOSEVELT CVN 71 at FPO AP 96632, using RDD 777 and VSM logistics protocols, and parcel post is strictly prohibited. Packaging must be palletized according to RP001 requirements and labeled in full compliance with DLA’s medical marking standards. The contract specifies a single purchase request quantity of one package, with a required delivery date of August 5, 2026, and procurement is managed by the Department of Defense’s Medical Supply Chain PHARM FSA. All bidders must provide detailed manufacturer and product information for FDA verification through EBS referral prior to award.